Literature DB >> 31437014

The Glycemic Gap and 90-Day Mortality in Community-acquired Pneumonia. A Prospective Cohort Study.

Andreas Vestergaard Jensen1,2, Gertrud Baunbæk Egelund1,2, Stine Bang Andersen1, Pelle Trier Petersen1, Thomas Benfield2,3, Martin Witzenrath4,5, Gernot Rohde5,6, Pernille Ravn2,7, Daniel Faurholt-Jepsen1.   

Abstract

Rationale: Hyperglycemia is associated with mortality in patients with community-acquired pneumonia (CAP), and hyperglycemia may be a biomarker of severity. However, hyperglycemia has a major disadvantage because the association is diminished in patients with diabetes mellitus (DM). This hampers the use of hyperglycemia as a biomarker. Accounting for habitual glucose levels could overcome this disadvantage.
Objectives: We hypothesized that the glycemic gap (the difference between plasma glucose and the estimated average glucose) may be associated with mortality irrespective of DM.
Methods: Among 1,933 adults with CAP included in a prospective multicenter cohort, we investigated the association between the glycemic gap and 90-day mortality. Hemoglobin A1c was used to estimate the average glucose. The association was assessed with Cox proportional hazard models after adjustment for age, sex, CURB-65 (Confusion, urea >7 mmol/L, respiratory rate ≥30 breaths/minute, systolic blood pressure <90 mmHg or diastolic blood pressure ≤60 mmHg and age ≥65 years), and comorbidities. In the prespecified analysis the absolute and relative glycemic gaps were used as a continuous variable. In a post hoc analysis, the absolute and relative glycemic gaps were used as a categorical variable grouped according to quartiles.
Results: In the post hoc analysis, patients with the lowest (negative) and highest (positive) absolute glycemic gap quartiles had increased risk of 90-day mortality (hazard ratio, 2.6; 95% confidence interval, 1.02-6.65; and hazard ratio, 2.5; 95% confidence interval, 1.01-6.06, respectively). A similar association was found for the relative glycemic gap. The associations were independent of age, CURB-65 score, sex, or number of comorbidities and not modified by DM.Conclusions: Patients with the highest and lowest glycemic gap may have an increased risk of 90-day mortality, and the association was not modified by DM. These associations were found in an exploratory post hoc analysis and should be validated in other populations before further conclusions can be made.

Entities:  

Keywords:  biomarker; community-acquired pneumonia; mortality; prognosis

Mesh:

Substances:

Year:  2019        PMID: 31437014     DOI: 10.1513/AnnalsATS.201901-007OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  6 in total

1.  Glycemia, Beta-Cell Function and Sensitivity to Insulin in Mildly to Critically Ill Covid-19 Patients.

Authors:  Ioannis Ilias; Aristidis Diamantopoulos; Maria Pratikaki; Efthymia Botoula; Edison Jahaj; Nikolaos Athanasiou; Stamatios Tsipilis; Alexandros Zacharis; Alice G Vassiliou; Dimitra A Vassiliadi; Anastasia Kotanidou; Stylianos Tsagarakis; Ioanna Dimopoulou
Journal:  Medicina (Kaunas)       Date:  2021-01-14       Impact factor: 2.430

2.  Glycemic variability assessed by continuous glucose monitoring in hospitalized patients with community-acquired pneumonia.

Authors:  Mikkel Thor Olsen; Arnold Matovu Dungu; Carina Kirstine Klarskov; Andreas Kryger Jensen; Birgitte Lindegaard; Peter Lommer Kristensen
Journal:  BMC Pulm Med       Date:  2022-03-09       Impact factor: 3.317

3.  Glucometabolic changes influence hospitalization and outcome in patients with COVID-19: An observational cohort study.

Authors:  Clara L Clausen; Christian Leo-Hansen; Daniel Faurholt-Jepsen; Rikke Krogh-Madsen; Christian Ritz; Ole Kirk; Henrik L Jørgensen; Thomas Benfield; Thomas P Almdal; Ole Snorgaard
Journal:  Diabetes Res Clin Pract       Date:  2022-04-25       Impact factor: 8.180

4.  Type 2 Diabetes Mellitus with Tight Glucose Control and Poor Pre-Injury Stair Climbing Capacity May Predict Postoperative Delirium: A Secondary Analysis.

Authors:  Kaixi Liu; Yanan Song; Yi Yuan; Zhengqian Li; Xiaoxiao Wang; Wenchao Zhang; Yue Li; Xinning Mi; Dengyang Han; Yulan Rong; Xiangyang Guo; Geng Wang
Journal:  Brain Sci       Date:  2022-07-20

5.  Impact of rapid molecular testing on diagnosis, treatment and management of community-acquired pneumonia in Norway: a pragmatic randomised controlled trial (CAPNOR).

Authors:  Sondre Serigstad; Christian Ritz; Daniel Faurholt-Jepsen; Dagfinn Markussen; Marit H Ebbesen; Øyvind Kommedal; Rune O Bjørneklett; Lars Heggelund; Tristan W Clark; Cornelis H van Werkhoven; Siri T Knoop; Elling Ulvestad; Harleen M S Grewal
Journal:  Trials       Date:  2022-08-01       Impact factor: 2.728

Review 6.  Unmet needs in pneumonia research: a comprehensive approach by the CAPNETZ study group.

Authors:  Mathias W Pletz; Andreas Vestergaard Jensen; Christina Bahrs; Claudia Davenport; Jan Rupp; Martin Witzenrath; Grit Barten-Neiner; Martin Kolditz; Sabine Dettmer; James D Chalmers; Daiana Stolz; Norbert Suttorp; Stefano Aliberti; Wolfgang M Kuebler; Gernot Rohde
Journal:  Respir Res       Date:  2022-09-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.